Allogene Therapeutics, Inc. Additional Paid in Capital, Common Stock
Allogene Therapeutics, Inc. (ALLO) had Additional Paid in Capital, Common Stock of $2.53 billion as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-12
- 2026-06-30: Additional Paid in Capital, Common Stock $2.53B.
- 2026-03-31: Additional Paid in Capital, Common Stock $2.33B.
- 2025-12-31: Additional Paid in Capital, Common Stock $2.30B.
- 2025-09-30: Additional Paid in Capital, Common Stock $2.29B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $2.53B 10-Q · filed 2026-08-12 |
| 2026-03-31 | $2.33B 10-Q · filed 2026-05-13 |
| 2025-12-31 | $2.30B 10-Q · filed 2026-08-12 |
| 2025-09-30 | $2.29B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.27B 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.26B 10-Q · filed 2025-05-13 |
| 2024-12-31 | $2.24B 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.22B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.21B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $2.09B 10-Q · filed 2024-05-13 |
| 2023-12-31 | $2.08B 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.06B 10-K · filed 2024-03-14 |
| 2023-06-30 | $2.04B 10-K · filed 2024-03-14 |
| 2023-03-31 | $1.93B 10-K · filed 2024-03-14 |
| 2022-12-31 | $1.91B 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $1.89B 10-K · filed 2024-03-14 |
| 2022-06-30 | $1.87B 10-K · filed 2024-03-14 |
| 2022-03-31 | $1.85B 10-K · filed 2024-03-14 |
| 2021-12-31 | $1.82B 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $1.80B 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.77B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $1.75B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.73B 10-K · filed 2022-02-23 |
| 2020-09-30 | $1.70B 10-Q · filed 2020-11-04 |
| 2020-06-30 | $1.67B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.06B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $1.02B 10-K · filed 2021-02-25 |
| 2019-09-30 | $952.82M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $937.71M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $922.82M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $914.26M 10-K · filed 2020-02-27 |
| 2018-09-30 | $12.69M 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |